ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer
Condition: Breast Cancer
Sponsor: Gilead Sciences, Inc.
Full Title
Protocol GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Study Treatment
Arm A: Anti-TROP2 antibody-drug conjugate sacituzumab govitecan + pembrolizumab
Arm B: pembrolizumab +/- capecitabine
Eligibility/Info
Non-metastatic triple negative breast cancer treated with neoadjuvant systemic therapy followed by surgery.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
